-
公开(公告)号：US20240066213A1
公开(公告)日：2024-02-29
申请号：US18453765
申请日：2023-08-22
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Jason O’CONNOR , Yibin ZHENG , Ashutosh ZADE
CPC classification number: A61M5/14248 , A61M5/1723 , A61M2202/0486
Abstract: Disclosed are techniques, devices and systems that modify an insulin delivery schedule based on how sensitive a diabetic user may to fluctuations in their total daily insulin or fluctuations in their blood glucose measurement values. As a control algorithm calculates how to adapt the calculation of the user's total daily insulin, a rate of adaptivity function may be used in the calculation. The rate of adaptivity may depend on a number of factors and the disclosed techniques, devices and systems enable calculation of the rate of adaptivity to provide effective implementation or modification of a diabetic treatment plan.
-
公开(公告)号：US20230310741A1
公开(公告)日：2023-10-05
申请号：US18192380
申请日：2023-03-29
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE , James CAUSEY
IPC: A61M5/172
CPC classification number: A61M5/172 , A61M2205/50
Abstract: Disclosed herein is a drug delivery system wherein wearable components of the system are provided with Wi-Fi and/or cellular capabilities such as to allow different modalities for inter-component communications and, further, to allow access to a plethora of cloud-based services to enhance the functionality of the system.
-
公开(公告)号：US20230166034A1
公开(公告)日：2023-06-01
申请号：US17752236
申请日：2022-05-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE
CPC classification number: A61M5/1723 , A61M5/14244 , G16H20/17 , A61M2230/201 , A61M2005/14208
Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.
-
公开(公告)号：US20220287633A1
公开(公告)日：2022-09-15
申请号：US17685937
申请日：2022-03-03
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Ashutosh ZADE , Joon Bok LEE
Abstract: Disclosed are processes and techniques implementable by devices and a drug delivery system to maintain optimal drug delivery for a user according to a user's diabetes treatment plan. The disclosed techniques enable a drug delivery device that received an analyte measurement value from an analyte sensor during a prior cycle time to determine a present analyte measurement value has not been received during a present cycle time. A processor of the drug delivery device may, in response to the determination, initiate an action to obtain the present analyte measure value from another device or an estimate of the present analyte measurement value. Based on an outcome of the initiated action, the processor may calculate a dosage of the drug using the present analyte measurement value or information related to the present analyte measurement value. The drug delivery device may also be operable to output the calculated dosage of the drug.
-
5.发明申请公开(公告)号：US20210244880A1
公开(公告)日：2021-08-12
申请号：US16788892
申请日：2020-02-12
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR , Trang LY , Yibin ZHENG , Connor GULLIFER , Kyle GROVER
Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
-
Patent Agency Ranking
公开(公告)号：US20210128831A1
公开(公告)日：2021-05-06
申请号：US17085344
申请日：2020-10-30
Applicant: Insulet Corporation
Inventor： Ashutosh ZADE , Joon Bok LEE , Yibin ZHENG , Rangarajan NARAYANASWAMI , David NAZZARO , Thomas METZMAKER
Abstract: A wearable drug delivery device and method for optimizing performance thereof are provided. A system may include a processor operable with memory, and a drug delivery device and sensor coupled to a user, the sensor operable to detect characteristics of the delivery device. A receiver operable on the processor receives an input signal from the sensor, the input signal representing the detected characteristics. A controller operable on the processor receives the input signal from the receiver, and retrieves, from memory, a baseline characteristics. The controller may determine a location of the delivery device and a tissue profile of the injection location based on a comparison between the detected characteristics and the baseline characteristics. The controller may further control or modify delivery of a liquid drug from the delivery device in response to the location of the delivery device.
-
公开(公告)号：US20250018114A1
公开(公告)日：2025-01-16
申请号：US18903653
申请日：2024-10-01
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Jason O’CONNOR , Yibin ZHENG , Ashutosh ZADE
IPC: A61M5/172 , A61B5/00 , A61B5/145 , A61K38/22 , A61K38/26 , A61K38/28 , A61M5/14 , A61M5/142 , G16H20/17 , G16H40/67
Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
-
8.发明公开公开(公告)号：US20240299660A1
公开(公告)日：2024-09-12
申请号：US18667224
申请日：2024-05-17
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR , Trang LY , Yibin ZHENG , Connor GULLIFER , Kyle GROVER
CPC classification number: A61M5/1723 , G16H20/17 , A61M2202/07 , A61M2205/18 , A61M2205/3569 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/583 , A61M2230/201
Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
-
9.发明公开公开(公告)号：US20240157055A1
公开(公告)日：2024-05-16
申请号：US18508361
申请日：2023-11-14
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE
CPC classification number: A61M5/1723 , G16H40/67 , G16H50/20 , G16H50/30 , A61M2005/14208
Abstract: A drug delivery system including a memory storing programming code operable to enable delivery of insulin and a processor operable to execute the programming code. When executed, the programming code causes the processor to: calculate a first aggregate insulin-on-board amount for a user based on a plurality of individual insulin-on-board estimates made over a first period of time, determine that the first aggregate insulin-on-board amount is greater than a maximum depot formation threshold amount, determine a first residual amount of insulin remaining in the first aggregate insulin-on-board amount, increase a subsequent calculation of an individual insulin-on-board estimate based on the first residual amount of insulin, and utilize the subsequent calculation of the individual insulin-on-board estimate in a calculation of a second aggregate insulin-on-board amount over a second period of time.
-
公开(公告)号：US20230310742A1
公开(公告)日：2023-10-05
申请号：US18190572
申请日：2023-03-27
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Eric BENJAMIN , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
CPC classification number: A61M5/1723 , A61M5/14244 , A61M5/16877 , A61M2205/3576 , A61M2205/52 , A61M2202/0486
Abstract: Disclosed are techniques, processes, systems, and programming code that enables users of automatic drug delivery devices to initiate the automatic drug delivery device for an initial use phase as well as implement changes that control the adjustment of target setpoints by a medication delivery algorithm used in the control of the automatic drug delivery device. During the initial use phase, the automatic drug delivery device may be based on the user's glucose control outcome without performing time consuming and frequent settings of sensor values as well as allowing users to remain substantially within range of any target setpoints. In addition, the disclosed techniques, processes, systems, and programming code enable users to have initial dosage settings automatically set without having to input what were previously considered fundamental inputs.
-
-
-
-
-
-
-
-
-
Search Results
45
records
(took 0.026 seconds)
